Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 224

1.

Uterine serous carcinoma: Reassessing effectiveness of platinum-based adjuvant therapy.

Tortorella L, Langstraat CL, Weaver AL, McGree ME, Bakkum-Gamez JN, Dowdy SC, Cliby WA, Keeney GL, Sherman ME, Weroha SJ, Mariani A, Podratz KC.

Gynecol Oncol. 2018 May;149(2):291-296. doi: 10.1016/j.ygyno.2018.02.022. Epub 2018 Mar 14.

PMID:
29550183
2.

Primary brain metastases of endometrial cancer: A report of 18 cases and review of the literature.

Uccella S, Morris JM, Multinu F, Cliby WA, Podratz KC, Gostout BS, Dowdy SC, Ghezzi F, Makdisi PB, Keeney GL, Link MJ, Mariani A.

Gynecol Oncol. 2016 Jul;142(1):70-75. doi: 10.1016/j.ygyno.2016.04.013. Epub 2016 Apr 26. Review.

PMID:
27095189
3.

The effect of diabetes and metformin on clinical outcomes is negligible in risk-adjusted endometrial cancer cohorts.

Al Hilli MM, Bakkum-Gamez JN, Mariani A, Cliby WA, Mc Gree ME, Weaver AL, Dowdy SC, Podratz KC.

Gynecol Oncol. 2016 Feb;140(2):270-6. doi: 10.1016/j.ygyno.2015.11.019. Epub 2015 Dec 1.

PMID:
26607780
4.

Pancreaticoduodenectomy in optimal primary cytoreduction of epithelial ovarian cancer: A case report and review of the literature.

Beissel JM, Kendrick ML, Podratz KC, Bakkum-Gamez JN.

Gynecol Oncol Rep. 2014 Sep 28;10:25-7. doi: 10.1016/j.gore.2014.09.001. eCollection 2014 Dec.

5.

Risk-adjusted outcomes in elderly endometrial cancer patients: implications of the contrasting impact of age on progression-free and cause-specific survival.

AlHilli MM, Bakkum-Gamez JN, Mariani A, Weaver AL, McGree ME, Keeney GL, Jatoi A, Dowdy SC, Podratz KC.

Gynecol Oncol. 2015 Jul;138(1):133-40. doi: 10.1016/j.ygyno.2015.04.010. Epub 2015 Apr 17.

PMID:
25895615
6.

Microarray analysis on gene regulation by estrogen, progesterone and tamoxifen in human endometrial stromal cells.

Ren CE, Zhu X, Li J, Lyle C, Dowdy S, Podratz KC, Byck D, Chen HB, Jiang SW.

Int J Mol Sci. 2015 Mar 13;16(3):5864-85. doi: 10.3390/ijms16035864.

7.

Detection of endometrial cancer via molecular analysis of DNA collected with vaginal tampons.

Bakkum-Gamez JN, Wentzensen N, Maurer MJ, Hawthorne KM, Voss JS, Kroneman TN, Famuyide AO, Clayton AC, Halling KC, Kerr SE, Cliby WA, Dowdy SC, Kipp BR, Mariani A, Oberg AL, Podratz KC, Shridhar V, Sherman ME.

Gynecol Oncol. 2015 Apr;137(1):14-22. doi: 10.1016/j.ygyno.2015.01.552. Epub 2015 Feb 10.

8.

Distribution and volume of extrauterine disease in uterine serous carcinoma: is minimally invasive surgery a suitable approach?

Ayeni TA, AlHilli MM, Bakkum-Gamez JN, Mariani A, McGree ME, Weaver AL, Cliby WA, Keeney GL, Podratz KC, Dowdy SC.

Int J Gynecol Cancer. 2015 Jan;25(1):87-91. doi: 10.1097/IGC.0000000000000326.

PMID:
25474625
9.

Prognostic and therapeutic relevance of molecular subtypes in high-grade serous ovarian cancer.

Konecny GE, Wang C, Hamidi H, Winterhoff B, Kalli KR, Dering J, Ginther C, Chen HW, Dowdy S, Cliby W, Gostout B, Podratz KC, Keeney G, Wang HJ, Hartmann LC, Slamon DJ, Goode EL.

J Natl Cancer Inst. 2014 Sep 30;106(10). pii: dju249. doi: 10.1093/jnci/dju249. Print 2014 Oct.

10.

Risk-scoring models for individualized prediction of overall survival in low-grade and high-grade endometrial cancer.

AlHilli MM, Mariani A, Bakkum-Gamez JN, Dowdy SC, Weaver AL, Peethambaram PP, Keeney GL, Cliby WA, Podratz KC.

Gynecol Oncol. 2014 Jun;133(3):485-93. doi: 10.1016/j.ygyno.2014.03.567. Epub 2014 Mar 29.

11.

Efficacy of contemporary chemotherapy in stage IIIC endometrial cancer: a histologic dichotomy.

Bakkum-Gamez JN, Mariani A, Dowdy SC, Weaver AL, McGree ME, Martin JR, Keeney GL, Jatoi A, Gostout BS, Podratz KC.

Gynecol Oncol. 2014 Mar;132(3):578-84. doi: 10.1016/j.ygyno.2014.01.007. Epub 2014 Jan 14.

12.

The impact of perioperative packed red blood cell transfusion on survival in epithelial ovarian cancer.

Warner LL, Dowdy SC, Martin JR, Lemens MA, McGree ME, Weaver AL, Podratz KC, Bakkum-Gamez JN.

Int J Gynecol Cancer. 2013 Nov;23(9):1612-9. doi: 10.1097/01.IGC.0000436089.03581.6b.

13.

Prospective assessment of the prevalence of pelvic, paraaortic and high paraaortic lymph node metastasis in endometrial cancer.

Kumar S, Podratz KC, Bakkum-Gamez JN, Dowdy SC, Weaver AL, McGree ME, Cliby WA, Keeney GL, Thomas G, Mariani A.

Gynecol Oncol. 2014 Jan;132(1):38-43. doi: 10.1016/j.ygyno.2013.10.002. Epub 2013 Oct 9.

14.

Hypomethylation and activation of syncytin-1 gene in endometriotic tissue.

Zhou H, Li J, Podratz KC, Tipton T, Marzolf S, Chen HB, Jiang SW.

Curr Pharm Des. 2014;20(11):1786-95.

PMID:
23888948
15.

Development of an intracellular, DNA methyltransferase-specific, and gene-specific assay for studying dynamic DNA methylation.

Gonzalez-Bosquet J, Chu Y, Chen HB, Dowdy SC, Podratz KC, Li J, Jiang SW.

Curr Pharm Des. 2014;20(11):1664-73.

PMID:
23888947
16.

Risk-scoring system for the individualized prediction of lymphatic dissemination in patients with endometrioid endometrial cancer.

AlHilli MM, Podratz KC, Dowdy SC, Bakkum-Gamez JN, Weaver AL, McGree ME, Keeney GL, Cliby WA, Mariani A.

Gynecol Oncol. 2013 Oct;131(1):103-8. doi: 10.1016/j.ygyno.2013.06.037. Epub 2013 Jul 9.

PMID:
23845691
17.

Risk factors that mitigate the role of paraaortic lymphadenectomy in uterine endometrioid cancer.

Kumar S, Mariani A, Bakkum-Gamez JN, Weaver AL, McGree ME, Keeney GL, Cliby WA, Podratz KC, Dowdy SC.

Gynecol Oncol. 2013 Sep;130(3):441-5. doi: 10.1016/j.ygyno.2013.05.035. Epub 2013 Jun 5.

PMID:
23747331
18.

Evaluating the prognostic significance of preoperative thrombocytosis in epithelial ovarian cancer.

Allensworth SK, Langstraat CL, Martin JR, Lemens MA, McGree ME, Weaver AL, Dowdy SC, Podratz KC, Bakkum-Gamez JN.

Gynecol Oncol. 2013 Sep;130(3):499-504. doi: 10.1016/j.ygyno.2013.05.038. Epub 2013 Jun 5.

19.

Bone metastases in endometrial cancer: report on 19 patients and review of the medical literature.

Uccella S, Morris JM, Bakkum-Gamez JN, Keeney GL, Podratz KC, Mariani A.

Gynecol Oncol. 2013 Sep;130(3):474-82. doi: 10.1016/j.ygyno.2013.05.010. Epub 2013 May 15. Review.

20.

Predictors and costs of surgical site infections in patients with endometrial cancer.

Bakkum-Gamez JN, Dowdy SC, Borah BJ, Haas LR, Mariani A, Martin JR, Weaver AL, McGree ME, Cliby WA, Podratz KC.

Gynecol Oncol. 2013 Jul;130(1):100-6. doi: 10.1016/j.ygyno.2013.03.022. Epub 2013 Apr 2.

21.

Comparative outcomes assessment of uterine grade 3 endometrioid, serous, and clear cell carcinomas.

Ayeni TA, Bakkum-Gamez JN, Mariani A, McGree ME, Weaver AL, Haddock MG, Keeney GL, Long HJ 3rd, Dowdy SC, Podratz KC.

Gynecol Oncol. 2013 Jun;129(3):478-85. doi: 10.1016/j.ygyno.2013.03.011. Epub 2013 Mar 25.

PMID:
23535279
22.

Factors predictive of postoperative morbidity and cost in patients with endometrial cancer.

Dowdy SC, Borah BJ, Bakkum-Gamez JN, Kumar S, Weaver AL, McGree ME, Haas LR, Cliby WA, Podratz KC.

Obstet Gynecol. 2012 Dec;120(6):1419-27. doi: http://10.1097/AOG.0b013e3182737538.

PMID:
23168769
23.

Impact of tubal ligation on routes of dissemination and overall survival in uterine serous carcinoma.

Ayeni TA, Bakkum-Gamez JN, Mariani A, McGree ME, Weaver AL, AlHilli MM, Martin JR, Keeney GL, Dowdy SC, Podratz KC.

Gynecol Oncol. 2013 Jan;128(1):71-76. doi: 10.1016/j.ygyno.2012.10.025. Epub 2012 Nov 2.

PMID:
23127971
24.

Preoperative biopsy and intraoperative tumor diameter predict lymph node dissemination in endometrial cancer.

AlHilli MM, Podratz KC, Dowdy SC, Bakkum-Gamez JN, Weaver AL, McGree ME, Kumar S, Keeney GL, Cliby WA, Mariani A.

Gynecol Oncol. 2013 Feb;128(2):294-9. doi: 10.1016/j.ygyno.2012.10.009. Epub 2012 Oct 17.

PMID:
23085458
25.

A prospective assessment of the reliability of frozen section to direct intraoperative decision making in endometrial cancer.

Kumar S, Medeiros F, Dowdy SC, Keeney GL, Bakkum-Gamez JN, Podratz KC, Cliby WA, Mariani A.

Gynecol Oncol. 2012 Dec;127(3):525-31. doi: 10.1016/j.ygyno.2012.08.024. Epub 2012 Aug 29.

PMID:
22940491
26.

Prospective assessment of survival, morbidity, and cost associated with lymphadenectomy in low-risk endometrial cancer.

Dowdy SC, Borah BJ, Bakkum-Gamez JN, Weaver AL, McGree ME, Haas LR, Keeney GL, Mariani A, Podratz KC.

Gynecol Oncol. 2012 Oct;127(1):5-10. doi: 10.1016/j.ygyno.2012.06.035. Epub 2012 Jul 3.

PMID:
22771890
27.

Incidence of and risk factors for postoperative ileus in women undergoing primary staging and debulking for epithelial ovarian carcinoma.

Bakkum-Gamez JN, Langstraat CL, Martin JR, Lemens MA, Weaver AL, Allensworth S, Dowdy SC, Cliby WA, Gostout BS, Podratz KC.

Gynecol Oncol. 2012 Jun;125(3):614-20. doi: 10.1016/j.ygyno.2012.02.027. Epub 2012 Feb 24.

28.

Incidence and factors associated with synchronous ovarian and endometrial cancer: a population-based case-control study.

AlHilli MM, Dowdy SC, Weaver AL, St Sauver JL, Keeney GL, Mariani A, Podratz KC, Bakkum-Gamez JN.

Gynecol Oncol. 2012 Apr;125(1):109-13. doi: 10.1016/j.ygyno.2011.12.444. Epub 2011 Dec 28.

29.

Aromatase inhibitors in the treatment of recurrent ovarian granulosa cell tumors: brief report and review of the literature.

Alhilli MM, Long HJ, Podratz KC, Bakkum-Gamez JN.

J Obstet Gynaecol Res. 2012 Jan;38(1):340-4. doi: 10.1111/j.1447-0756.2011.01698.x. Epub 2011 Dec 5. Review.

PMID:
22136798
30.

The impact of surgical guidelines and periodic quality assessment on the staging of endometrial cancer.

Bakkum-Gamez JN, Mariani A, Dowdy SC, Weaver AL, McGree ME, Cliby WA, Gostout BS, Stanhope CR, Wilson TO, Podratz KC.

Gynecol Oncol. 2011 Oct;123(1):58-64. doi: 10.1016/j.ygyno.2011.06.018. Epub 2011 Jul 13.

PMID:
21741696
31.

Risk factors for developing multiple malignancies in patients with endometrial cancer.

Uccella S, Cha SS, Melton LJ 3rd, Bergstralh EJ, Boardman LA, Keeney GL, Podratz KC, Ciancio FF, Mariani A.

Int J Gynecol Cancer. 2011 Jul;21(5):896-901. doi: 10.1097/IGC.0b013e318219711f.

32.

Expression and functional significance of HtrA1 loss in endometrial cancer.

Mullany SA, Moslemi-Kebria M, Rattan R, Khurana A, Clayton A, Ota T, Mariani A, Podratz KC, Chien J, Shridhar V.

Clin Cancer Res. 2011 Feb 1;17(3):427-36. doi: 10.1158/1078-0432.CCR-09-3069. Epub 2010 Nov 23.

33.

Resection of the inferior vena cava for an isolated para-aortic recurrence of endometrial cancer: report of a case.

Uccella S, Mariani A, Nagorney DM, Kalra M, Haddock MG, Podratz KC.

Gynecol Oncol. 2010 Oct;119(1):167-8. doi: 10.1016/j.ygyno.2010.06.005. Epub 2010 Jul 6. No abstract available.

PMID:
20609465
34.

Referral and ascertainment bias in patients with synchronous and metachronous endometrial malignancy.

Mariani A, Cha SS, Bergstralh EJ, Boardman LA, Dowdy SC, Keeney GL, Podratz KC, Melton LJ 3rd.

Eur J Gynaecol Oncol. 2010;31(1):5-9.

35.

Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer.

Galanis E, Hartmann LC, Cliby WA, Long HJ, Peethambaram PP, Barrette BA, Kaur JS, Haluska PJ Jr, Aderca I, Zollman PJ, Sloan JA, Keeney G, Atherton PJ, Podratz KC, Dowdy SC, Stanhope CR, Wilson TO, Federspiel MJ, Peng KW, Russell SJ.

Cancer Res. 2010 Feb 1;70(3):875-82. doi: 10.1158/0008-5472.CAN-09-2762. Epub 2010 Jan 26.

36.

The impact of multi-modal therapy on survival for uterine carcinosarcomas.

Gonzalez Bosquet J, Terstriep SA, Cliby WA, Brown-Jones M, Kaur JS, Podratz KC, Keeney GL.

Gynecol Oncol. 2010 Mar;116(3):419-23. doi: 10.1016/j.ygyno.2009.10.053. Epub 2009 Nov 5.

PMID:
19896181
37.

Soluble epidermal growth factor receptor: a biomarker of epithelial ovarian cancer.

Baron AT, Lafky JM, Boardman CH, Cora EM, Buenafe MC, Liu D, Rademaker A, Fishman DA, Podratz KC, Reiter JL, Maihle NJ.

Cancer Treat Res. 2009;149:189-202. doi: 10.1007/978-0-387-98094-2_9. Review. No abstract available.

PMID:
19763437
38.

Re: Systematic pelvic lymphadenectomy vs no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial.

Uccella S, Podratz KC, Aletti GD, Mariani A.

J Natl Cancer Inst. 2009 Jun 16;101(12):897-8; author reply 898-9. doi: 10.1093/jnci/djp124. Epub 2009 Jun 9. No abstract available.

PMID:
19509367
39.

Quality improvement in the surgical approach to advanced ovarian cancer: the Mayo Clinic experience.

Aletti GD, Dowdy SC, Gostout BS, Jones MB, Stanhope RC, Wilson TO, Podratz KC, Cliby WA.

J Am Coll Surg. 2009 Apr;208(4):614-20. doi: 10.1016/j.jamcollsurg.2009.01.006.

PMID:
19476798
40.

Endometrial stromal sarcoma: treatment and patterns of recurrence.

Thomas MB, Keeney GL, Podratz KC, Dowdy SC.

Int J Gynecol Cancer. 2009 Feb;19(2):253-6. doi: 10.1111/IGC.0b013e3181999c5f.

PMID:
19396004
41.

Pattern of retroperitoneal dissemination of primary peritoneum cancer: basis for rational use of lymphadenectomy.

Aletti GD, Powless C, Bakkum-Gamez J, Wilson TO, Podratz KC, Cliby WA.

Gynecol Oncol. 2009 Jul;114(1):32-6. doi: 10.1016/j.ygyno.2009.03.020. Epub 2009 Apr 9.

PMID:
19361840
42.

Lymphadenectomy in endometrial cancer.

Uccella S, Podratz KC, Aletti GD, Mariani A.

Lancet. 2009 Apr 4;373(9670):1170; author reply 1170-1. doi: 10.1016/S0140-6736(09)60677-2. No abstract available.

PMID:
19345823
43.

New surgical staging of endometrial cancer: 20 years later.

Mariani A, Dowdy SC, Podratz KC.

Int J Gynaecol Obstet. 2009 May;105(2):110-1. doi: 10.1016/j.ijgo.2009.02.008. Epub 2009 Mar 14. No abstract available.

PMID:
19285672
44.

Audit of suspected chronic intestinal pseudo-obstruction in patients with gynecologic cancer.

Mariani A, Camilleri M, Petersen IA, Ward EM, Farrugia G, Kelly DG, Podratz KC.

Eur J Gynaecol Oncol. 2008;29(6):578-82.

PMID:
19115682
45.

HER2 gene amplification and EGFR expression in a large cohort of surgically staged patients with nonendometrioid (type II) endometrial cancer.

Konecny GE, Santos L, Winterhoff B, Hatmal M, Keeney GL, Mariani A, Jones M, Neuper C, Thomas B, Muderspach L, Riehle D, Wang HJ, Dowdy S, Podratz KC, Press MF.

Br J Cancer. 2009 Jan 13;100(1):89-95. doi: 10.1038/sj.bjc.6604814. Epub 2008 Dec 16.

46.

Aggressive and complex surgery for advanced ovarian cancer: an economic analysis.

Aletti GD, Podratz KC, Moriarty JP, Cliby WA, Long KH.

Gynecol Oncol. 2009 Jan;112(1):16-21. doi: 10.1016/j.ygyno.2008.10.008. Epub 2008 Nov 22.

PMID:
19027146
47.

Stage IV ovarian cancer: disease site-specific rationale for postoperative treatment.

Aletti GD, Podratz KC, Cliby WA, Gostout BS.

Gynecol Oncol. 2009 Jan;112(1):22-7. doi: 10.1016/j.ygyno.2008.09.010. Epub 2008 Oct 23.

PMID:
18947860
48.

Extra-peritoneal laparoscopic para-aortic lymphadenectomy--a prospective cohort study of 293 patients with endometrial cancer.

Dowdy SC, Aletti G, Cliby WA, Podratz KC, Mariani A.

Gynecol Oncol. 2008 Dec;111(3):418-24. doi: 10.1016/j.ygyno.2008.08.021. Epub 2008 Oct 2.

49.

Rationale for folate receptor alpha targeted therapy in "high risk" endometrial carcinomas.

Brown Jones M, Neuper C, Clayton A, Mariani A, Konecny G, Thomas MB, Keeney G, Hartmann L, Podratz KC.

Int J Cancer. 2008 Oct 1;123(7):1699-703. doi: 10.1002/ijc.23686.

50.

Clear cell carcinoma of the cervix: a multi-institutional review in the post-DES era.

Thomas MB, Wright JD, Leiser AL, Chi DS, Mutch DG, Podratz KC, Dowdy SC.

Gynecol Oncol. 2008 Jun;109(3):335-9. doi: 10.1016/j.ygyno.2008.02.007. Epub 2008 Apr 3.

Supplemental Content

Loading ...
Support Center